Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Clearside Biomedical, Inc. (NASDAQ: CLSD).

Full DD Report for CLSD

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLSD)

Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
ALPHARETTA, Ga., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, ...
Source: GlobeNewswire
Date: November, 07 2018 16:30
Today's Research Reports on Stocks to Watch: Teladoc Health and Clearside
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in the red on disappointing trial results. RDI Initiates Coverage on: Teladoc Health, Inc...
Source: ACCESSWIRE IA
Date: November, 06 2018 07:55
Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 - Conference Call to Follow
ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results wi...
Source: GlobeNewswire
Date: November, 05 2018 16:30
Microcaps mostly among midday movers
More news on: Datawatch Corporation, JinkoSolar Holding Co., Ltd., Yulong Eco-Materials, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 12:46
SYY and SOGO among premarket losers on Q3 earnings
Clearside Biomedical (NASDAQ: CLSD )  -51%  on SAPPHIRE Phase 3 study failing to meet its primary endpoint. More news on: Clearside Biomedical, Diana Containerships Inc., Sysco Corporation, Stocks on the move, , Top stock market news, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 09:14
Clearside Bio's Xipere flunks late-stage retinal vein occlusion study; shares down 27% premarket
Thinly traded micro cap Clearside Biomedical (NASDAQ: CLSD ) is down  27%  premarket on light volume in response to its announcement that a Phase 3 clinical trial, SAPPHIRE , evaluating XIPERE (formerly suprachoroidal CLS-TA) in patients with retinal vein occlusion failed to ach...
Source: SeekingAlpha
Date: November, 05 2018 07:39
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data - ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceuti...
Source: GlobeNewswire
Date: November, 05 2018 07:00
Our Take On Clearside Biomedical
"Wine makes all things possible .” ― George R.R. Martin, The Mystery Knight Today, we look at a small biotech concern that a few followers have asked about lately. We have updated some previously exclusive research provided on this name to Biotech Forum members last month wi...
Source: SeekingAlpha
Date: October, 29 2018 13:58
Presentation of Additional Analyses of Clearside's PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE(TM) in Treating Uveitic Macular Edema
ALPHARETTA, Ga., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that additional  data from PEACHTREE, the c...
Source: GlobeNewswire
Date: October, 29 2018 10:25
Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer
ALPHARETTA, Ga., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas A. Ciulla, M.D., M.B.A...
Source: GlobeNewswire
Date: October, 25 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-018.818.258.958.23651,529
2018-07-318.858.919.058.70358,804
2018-07-308.578.788.908.235245,651
2018-07-279.018.569.018.44199,715
2018-07-269.308.969.408.91229,785

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1226,67568,09739.1721Short
2018-12-1125,65749,11252.2418Short
2018-12-1043,366120,60535.9570Short
2018-12-0734,79197,04835.8493Short
2018-12-0641,31453,38677.3873Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLSD.


About Clearside Biomedical, Inc. (NASDAQ: CLSD)

Logo for Clearside Biomedical, Inc. (NASDAQ: CLSD)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $371,787,766 - 05/11/2018
  • Issue and Outstanding: 31,913,113 - 03/12/2018

 


Recent Filings from (NASDAQ: CLSD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018

 

 


Daily Technical Chart for (NASDAQ: CLSD)

Daily Technical Chart for (NASDAQ: CLSD)


Stay tuned for daily updates and more on (NASDAQ: CLSD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLSD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLSD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLSD and does not buy, sell, or trade any shares of CLSD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/